Skip to main content

Natural-abundance carbon isotope profiling of long-chain polyunsaturated fatty acid supplement incorporation in extremely preterm infants: a sub-study of the Mega Donna Mega randomized clinical trial

In brief

Isotope testing detected supplemented fats in preterm infants within two weeks

In a 25-infant study, carbon isotope profiling detected supplemented arachidonic acid and DHA in circulating phospholipids by 10 to 16 days after treatment began, before standard fatty acid levels clearly differed between groups. The findings suggest concentration tests can miss early exposure, but the small study leaves uncertainty about how reliably the method tracks both fats.

Journal
The American journal of clinical nutrition (Q1)
Published
18 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Chuck T Chen, Ulrika Sjöbom, Mats X Andersson, Richard P Bazinet, Ann Hellström, Anders K Nilsson
PMID
43051547
DOI
10.1016/j.ajcnut.2026.101636

Why clinicians should know about it

  • Picked for Biochemistry (medical) (paper of the day, 21 November 2026): Stable-isotope profiling measures fatty acid bioavailability in preterm infants

Abstract

BACKGROUND: Extremely preterm infants are deprived of most third-trimester long-chain polyunsaturated fatty acid accretion. In the Mega Donna Mega trial, enteral arachidonic acid (ARA) and docosahexaenoic acid (DHA) supplementation reduced severe retinopathy of prematurity despite modest early changes in circulating levels. OBJECTIVE: We investigated whether natural-abundance carbon isotope ratio (δ13C) profiling detects early entry of supplemented ARA and DHA into circulating phospholipids in extremely preterm infants. METHODS: This sub-study of the randomized Mega Donna Mega trial included 25 infants born before 25+2 weeks' gestation who received standard-of-care nutrition (SOC, n=12) or enteral ARA+DHA supplementation (intervention, n=13; 100 and 50 mg/kg/day, respectively) from ≤3 days after birth until 40 weeks' postmenstrual age. Serum phospholipid fatty acid composition and δ13C values were determined at Day 0-3, 10-16, 34-47, and 75-87. Group differences were assessed with mixed models of treatment group by sampling window. RESULTS: Between-group differences in ARA and DHA weight percent (wt%) emerged late in the intervention (Day 75-87, mean [SD]: ARA 10.1 [2.0] versus 6.9 [1.4]; DHA 3.3 [1.0] versus 2.3 [0.7]). ARA and DHA δ13C were similar between groups at Day 0-3 and higher in supplemented infants from Day 10-16 (difference [95% CI]: ARA 1.9 [0.9, 2.8] mUr; DHA 2.0 [0.3, 3.6] mUr). The group-by-window interaction was significant for ARA δ13C (p=0.007) but not for DHA δ13C (p=0.11; p=0.005 after excluding one infant with necrotizing enterocolitis and low compliance). CONCLUSIONS: Natural-abundance δ13C profiling showed that supplemented ARA and DHA were bioavailable and entered circulating phospholipids within two weeks of birth, before clear separation in fatty acid composition. Concentration-based biomarkers may underestimate early exposure to supplemented fatty acids in extremely preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03201588, https://clinicaltrials.gov/study/NCT03201588.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.